with
5-azacytidine. Cell, 40(3), 485-486 (1985).
2. Glover, A.B. and Leyland-Jones, B., Biochemistry
of azacitidine: a review. Cancer Treatment
Reports, 71(10), 959-964 (1987).
3. Taylor.
/51/52 příslušenství
viz stranu 48/49/50/51/52 příslušenství
RS232/422/485,
Relé,
Pedálový spínač
RS232/422/485,
Relé,
Pedálový spínač
Volitelné
*Nové objednací číslo je
platné od
o
l
.
1
9
N
o
.
2
52. de la Fuente-Garcia, M.A., et al., Blood, 9, 2800-2809 (1998).
53. Autschbach, F., et al., Tissue Antigens, 54, 485-498 (1999).
54. Palou, E., et al., Immunol
R. et al., PLoS Pathogens, 6, e1001021 (2010).
28. Belyaev, N.N. et al., Nature immunol., 11, 477-485 (2010).
29. Eshel, R., et al., J. Cancer Ther. 1, 142-151 (2010).
30. Esmann, L., et al., J. Immunol
R. et al., PLoS Pathogens, 6, e1001021 (2010).
28. Belyaev, N.N. et al., Nature immunol., 11, 477-485 (2010).
29. Eshel, R., et al., J. Cancer Ther. 1, 142-151 (2010).
30. Esmann, L., et al., J. Immunol
.
4 Furuichi, M. et al. (1994) Genomics 24, 485-490
5 Kasahara, N. et al (1995) Mammalian Genome 6, 52-54.
6 Kondoh, Y et al. (1995) Cytogenet. Cell Genet. 71, 96-98.
7 Sawada, J. et al. (1995) Jpn. J.
reader (PerkinElmer, Boston, MA).]
f. Determine the fluorescent absorbance using wavelengths of 485 nm
excitation and 535 nm emission.
g. Calculate the percent of lucifer yellow passage across the
o
l
.
1
9
N
o
.
2
52. de la Fuente-Garcia, M.A., et al., Blood, 9, 2800-2809 (1998).
53. Autschbach, F., et al., Tissue Antigens, 54, 485-498 (1999).
54. Palou, E., et al., Immunol
MeSiCl3/Ph2SO/TFA [58, 71]. This method
provides an extra level of selectivity, and has been used to prepare
regioselectively peptides containing up to three disulfide bridges [71].
Similarly, Cys(tBu